STAAR Surgical Company - 10-Q Filing Summary
Business Context and Reporting Period
Company: STAAR Surgical Company (STAAR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 2, 2009
Business Overview: STAAR develops, manufactures, and sells visual implants (Intraocular Lenses - IOLs, and Implantable Collamer Lenses - ICLs) and other ophthalmic products. Operations are global, with manufacturing in the U.S., Switzerland, and Japan, and sales in approximately 50 countries.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Oct 2, 2009 | Nine Months Ended Oct 2, 2009 | Nine Months Ended Sep 26, 2008 |
|---|---|---|---|
| Net Sales | $18,113 | $55,514 | $56,737 |
| Gross Profit | $9,835 | $30,839 | $29,747 |
| Gross Margin | 54.3% | 55.6% | 52.4% |
| Operating Loss | $(1,169) | $(2,966) | $(12,136) |
| Net Loss | $(1,967) | $(4,717) | $(13,735) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.15) | $(0.47) |
| Cash from Operating Activities | $464 (Q3 only) | $302 | $(7,237) |
| Cash and Cash Equivalents (End of Period) | $5,644 | $5,644 | $6,697 |
| Restricted Cash | $7,368 | $7,368 | $0 |
Liquidity and Debt:
- Total Current Assets: $39.9 million (Oct 2, 2009) vs. $32.3 million (Jan 2, 2009).
- Total Current Liabilities: $21.8 million (Oct 2, 2009) vs. $21.5 million (Jan 2, 2009).
- Long-Term Debt: $4.4 million (Broadwood Note, net of discount) and $1.1 million (Capital Leases).
- Preferred Stock: $6.8 million Series A Redeemable Convertible Preferred Stock (mezzanine equity).
Material Changes vs. Prior Period
- Revenue Stability: Net sales remained flat for the quarter ($18.1M) but declined 2.2% year-to-date ($55.5M vs. $56.7M), primarily due to unfavorable foreign currency exchange rates (weaker Euro) and a strategic de-emphasis of low-margin non-IOL/ICL products.
- Improved Profitability: Operating loss narrowed significantly year-to-date from $12.1M to $3.0M. This improvement is driven by cost reduction efforts (operating expenses down $8.1M YTD) and the absence of the $3.9M loss on settlement of a pre-existing distribution arrangement recorded in the prior year.
- Cash Flow Turnaround: The company generated positive cash flow from operations ($302k) for the nine months ended Oct 2, 2009, a stark contrast to the $7.2M cash used in the prior year period.
- Product Mix: ICL sales grew 9% YTD internationally and 2% in the U.S., while IOL sales declined slightly in the U.S. but grew internationally. The company is shifting toward higher-margin aspheric IOLs and ICLs.
Guidance, Outlook, Risks, and Contingencies
Management Commentary & Strategy:
- Management focuses on improving cash flow, increasing gross margins, and cost reduction.
- Strategic goals include securing FDA approval for the Visian Toric ICL (TICL) and expanding ICL market share in key territories (U.S., China, Germany, India, Korea, Spain, Latin America).
- The "Centers of Excellence" program is being implemented to rationalize manufacturing (IOLs in U.S., delivery systems in Japan) to reduce costs.
Going Concern & Liquidity Risks:
- The company previously faced substantial doubt regarding its ability to continue as a going concern. Management believes this has been alleviated by positive operating cash flows and a recent equity offering.
- Equity Offering: In June 2009, STAAR raised $8.5 million via a public stock offering. Proceeds were primarily used to post a $7.3 million restricted cash deposit with the court to stay enforcement of the Parallax judgment.
- Debt Obligations: A $5 million Senior Secured Promissory Note to Broadwood Partners is due December 14, 2010. Interest is currently accruing at a default rate of 20% per annum (reducible to 7% if litigation is resolved).
- Preferred Stock Redemption: Holders of 1.7 million shares of Series A Preferred Stock have the right to redeem shares at $4.00/share ($6.8M aggregate) starting December 29, 2010, subject to solvency.
Legal Contingencies:
- Parallax Case: Final judgment of ~$5.0 million (actual + punitive damages) was rendered against STAAR. A $7.3 million deposit has been posted to stay enforcement pending appeal. STAAR intends to appeal vigorously.
- Moody Case: A similar lawsuit by former representative Scott C. Moody, Inc. seeks $32 million in damages. Trial commenced October 19, 2009. STAAR cannot estimate the potential loss, but notes that a judgment similar to Parallax could exceed available cash resources.
- Insurance: Insurers agreed to cover a portion of legal defense fees for both cases but reserved rights and will not cover punitive damages.
Investor Verification Checklist
- Restricted Cash Status: Verify the $7.3 million restricted cash deposit remains intact and the status of the Parallax appeal.
- Moody Litigation Outcome: Monitor the trial progress and potential judgment in the Moody case, which poses a significant liquidity risk if the outcome is adverse.
- Broadwood Note Compliance: Confirm the company remains in compliance with the Broadwood Note covenants and assess the ability to refinance or repay the $5 million principal due in December 2010.
- Preferred Stock Redemption: Assess the company's liquidity position relative to the potential $6.8 million redemption obligation for Series A Preferred Stock in late 2010.
- Regulatory Approvals: Track the FDA review status of the TICL application following the removal of the "integrity hold" in July 2009.
- Operating Cash Flow Sustainability: Verify if positive operating cash flow trends continue in the fourth quarter to support operations without further dilution.